XBI SPDR S&P BIOTECH ETF

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "XBI SPDR S&P BIOTECH ETF"

Transcription

1 SPDR S&P BIOTECH ETF ETF.com segment: Equity: U.S. Biotech Competing ETFs: FBT, BBC, CNCR, BBP, IBB Related ETF Channels: North America, Biotech, Equal-Weighted, Smart-Beta ETFs, S&P Biotechnology Select Industry Index, Healthcare, U.S., Biotechnology, Equity, Sectors Find more ETFs with our ETF Screener and Database *Unless otherwise stated, data provided by FactSet. A 66 FUND DESCRIPTION The SPDR S&P Biotech ETF tracks an equal-weighted index of US biotechnology stocks. FACTSET ANALYTICS INSIGHT provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund s alternative take on the space earns it a place on our Opportunities List. SUMMARY DATA Issuer Brand Inception Date Legal Structure Expense Ratio Assets Under Management Average Daily $ Average Spread (%) State Street Global Advisors SPDR 01/31/06 Open-Ended Fund 0.35% $4.79B $445.77M 0.03% PORTFOLIO DATA MSCI ESG ANALYTICS INSIGHT The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of November 5, 2018 the SPDR S&P BIOTECH ETF MSCI ESG Fund Quality Score is 3.83 out of 10. The fund s Peer Rank reflects the ranking of a fund s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ranks in the 5th percentile within its peer group and in the 6th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage. Weighted Average Market Cap Price / Earnings Ratio Price / Book Ratio Distribution Yield Next Ex-Dividend Date Number of Holdings $11.47B % 12/21/ INDEX DATA Index Tracked S&P Biotechnology Select Industry Index Index Weighting Methodology Index Selection Methodology Equal Market Cap Thomson Reuters US Biotechnology & Medical Research

2 1 Year Daily Price ($) Dec `18 Feb Mar Apr May Jun Jul Aug Sep Oct Nov 20M PERFORMANCE [as of 11/05/18] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS -7.67% % -1.41% -2.21% 6.04% 16.29% 17.08% (NAV) -7.91% % -1.45% -2.32% 5.99% 16.27% 17.06% S&P Biotechnology Select Industry Index -7.91% % -1.56% -2.38% 5.89% 15.87% 17.06% Thomson Reuters US Biotechnology &-7.41% -7.56% 2.82% 0.73% 1.45% 12.48% -- Medical Research All returns over 1 year are annualized. All returns are total returns unless otherwise stated. TOP 10 COUNTRIES United States % TOP 10 SECTORS Biotechnology & Medical 75.48% Biopharmaceuticals 0.58% Pharmaceuticals - NEC 10.26% Bio Diagnostics & Testing 0.36% Bio Therapeutic Drugs 8.56% Medical Equipment, Supp 1.30% Advanced Medical Equipm 1.20% TOP 10 HOLDINGS ACADIA Pharmaceuticals 2.25% Viking Therapeutics, Inc. 1.57% Esperion Therapeutics, In 1.78% Loxo Oncology Inc 1.53% Array BioPharma Inc. 1.71% Exelixis, Inc. 1.51% Ionis Pharmaceuticals, Inc. 1.62% Alexion Pharmaceuticals, 1.50% Immunomedics, Inc. 1.59% Incyte Corporation 1.46% Total Top 10 Weighting 16.52%

3 PORTFOLIO MANAGEMENT TAX EXPOSURES FUND STRUCTURE Expense Ratio Median Tracking Difference (12 Mo) Max. Upside Deviation (12 Mo) Max. Downside Deviation (12 Mo) 0.35% 0.02% 0.10% -0.17% Max LT/ST Capital Gains Rate Capital Gains Distributions (3 Year) Tax on Distributions Distributes K % / 39.60% -- Qualified dividends No Legal Structure OTC Derivative Use Securities Lending Active Securities Lending Split (Fund/Issuer) ETN Counterparty Open-Ended Fund No Yes 100% / 0% N/A ETN Counterparty Risk N/A Fund Closure Risk Low Portfolio Disclosure Daily

4 Daily Spread 0.12% FACTSET ANALYTICS BLOCK LIQUIDITY As of 11/06/ % 0.06% 0.03% 0% This measurement shows how easy it is to trade a $1 million USD block of. is rated a 5 out of 5. Premium/Discount 1.0% 0.5% TRADABILITY Avg. Daily Share 5,118, % -0.5% -1.0% Average Daily $ Median Daily Share $445.77M 4,163, % 20M 15M 10M 5M Median Daily ($) Average Spread (%) Average Spread ($) $375.89M 0.03% $0.03 Dec Feb Apr May Jul Sep Oct Median Premium / Discount (12 Mo) -0.01% Max. Premium / Discount (12 Mo) 0.52% / -1.05% Impediment to Creations None Market Hours Overlap % Creation Unit Size (Shares) 50,000 Creation Unit/Day (45 Day Average) Creation Unit Cost (%) 0.01% Underlying / Unit -- Open Interest on ETF Options 711,203 Net Asset Value (Yesterday) $83.43 ETF.com Implied Liquidity 5

5 SECTOR/INDUSTRY BREAKDOWN TOP 10 HOLDINGS PERFORMANCE STATISTICS Biotechnology & Medical Research - NEC Pharmaceuticals - NEC Bio Therapeutic Drugs 75.48% 85.67% 10.26% 0.49% 8.56% 4.30% ACADIA Pharmaceuticals Inc. Esperion Therapeutics, Inc. Array BioPharma Inc. Ionis Pharmaceuticals, Inc. Immunomedics, Inc. Viking Therapeutics, Inc. Loxo Oncology Inc Exelixis, Inc. Alexion Pharmaceuticals, Inc. 2.25% 1.78% 1.71% 1.62% 1.59% 1.57% 1.53% 1.51% 1.50% Goodness of Fit (R2) Beta Up Beta Down Beta Downside Standard Deviation % Thomson Reuters US Biotechnology & Medical Research Medical Equipment, Supplies & Distribution - NEC Advanced Medical Equipment & Technology - NEC 1.30% % -- Incyte Corporation Total Top 10 Weighting 1.46% 16.52% MSCI ESG RATINGS MSCI ESG Quality Score Peer Group Percentile Rank Global Percentile Rank SRI Screening Criteria Exposure 3.83 / % Biopharmaceuticals 0.58% 0.17% Bio Diagnostics & Testing 0.36% 0.27% Exposure to Sustainable Impact Solutions Weighted Average Carbon Intensity (t CO2e/$M Sales) 9.37% COUNTRIES United States % % REGIONS North America % % BENCHMARK COMPARISON HOLDINGS Number of Holdings Constituents Shared Holdings Shared Holdings Weight % ECONOMIC DEVELOPMENT BENCHMARK COMPARISON SUMMARY Developed Countries % % Number of Holdings Weighted Average Market Cap $11.47B $34.32B Price / Earnings Ratio Price / Book Ratio Dividend Yield % 0.65% Concentration Low --

6 2018 ETF.com The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional. ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com. [ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Data provider: Terms of Use MSCI ESG Research LLC s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.